CooperCompanies Cuts Outlook as Lens Destocking Weighs on Growth

CooperCompanies is taking a hit now to clear an inventory overhang it says had been building across U.S. contact-lens distributors, a move that is depressing reported revenue even as consumer consumption remains healthier underneath.

The medical-device maker cut its fiscal 2026 outlook after CooperVision revenue stalled at $717 million in the third quarter ended July 31. Consolidated revenue rose just 1% to $1.066 billion, while adjusted earnings per share reached $1.15, beating expectations. The more consequential number was the fourth-quarter forecast: CooperVision revenue of $692 million to $706 million, implying organic growth between negative 2% and flat.

Chief Executive Al White said U.S. consumption increased at a mid-single-digit rate during the quarter and in the first month of the fourth quarter. The revenue shortfall, he told analysts, was tied to channel inventory rather than a sudden collapse in end-market demand. Cooper expects to remove roughly the remaining half of the excess stock in the December quarter, after taking similar action in the third quarter.

That distinction matters, but it does not make the problem painless. Distributors had stocked up ahead of price increases, new private-label contracts and technology upgrades, leaving Cooper to absorb the reversal. Legacy hydrogel products also declined by double digits as the company rationalizes older offerings, adding another drag before fiscal 2027.

Cooper now expects fiscal 2026 revenue of roughly $4.23 billion to $4.25 billion, down from its prior range of $4.29 billion to $4.32 billion. Adjusted EPS guidance fell to $4.51 to $4.55 from $4.58 to $4.66. CooperSurgical remains the steadier leg, with fourth-quarter organic growth projected at 4% to 6%, supported by fertility and women’s-health products.

Management is responding with expanded sales coverage, heavier customer marketing and new inventory and logistics systems. The company also completed a strategic review without selling CooperSurgical, arguing that potential bids failed to reflect the unit’s long-term value. For shareholders, the near-term question is whether CooperVision can convert its product pipeline and contract wins into sales once the channel is clean. The company says it can return to market-level growth in 2027. Investors will want proof, not another reset.